Ratings by Credit Suisse (Brad Canino)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/7/2021 | Affimed Therapeutics | AFMD | Maintain | Outperform (N/A) |
|
Details | ||
| 3/31/2021 | Deciphera | DCPH | New Coverage | Outperform (N/A) |
40.40 (25.59) |
-36.66% | Details | |
| 3/31/2021 | Blueprint Medicines | BPMC | New Coverage | Neutral (N/A) |
92.01 (129.46) |
40.7% | Details | |
| 3/31/2021 | Exelixis | EXEL | New Coverage | Outperform (N/A) |
22.08 (54.08) |
144.93% | Details | |
| 3/31/2021 | Epizyme | EPZM | New Coverage | Outperform (N/A) |
7.45 (1.47) |
-80.27% | Details | |
| 3/31/2021 | Zymeworks | ZYME | New Coverage | Outperform (N/A) |
29.83 (28.67) |
-3.89% | Details | |
| 3/31/2021 | Affimed Therapeutics | AFMD | New Coverage | Outperform (N/A) |
7.32 (0.18) |
-97.54% | Details | |
| 3/31/2021 | Mersana | MRSN | New Coverage | Neutral (N/A) |
15.97 (29.08) |
82.09% | Details | |
| 3/31/2021 | Seagen | SGEN | New Coverage | Neutral (N/A) |
139.93 (228.74) |
63.47% | Details |
